Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M7,514Revenue (TTM) $M668Net Margin (%)-41.2Altman Z-Score8.0
Enterprise Value $M7,205EPS (TTM) $-1.8Operating Margin %-40.2Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.8Pre-tax Margin (%)-41.3Higher ROA y-yN
Price/Book6.010-y EBITDA Growth Rate %--Quick Ratio3.7Cash flow > EarningsY
Price/Sales11.25-y EBITDA Growth Rate %--Current Ratio3.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %-536.1ROA % (ttm)-14.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-20.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M152ROIC % (ttm)-26.9Gross Margin Increase y-yY

Gurus Latest Trades with ALKS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALKSKen Fisher 2016-06-30 Add$34.19 - $47
($41.15)
$ 49.5820%Add 2.33%123,094
ALKSVanguard Health Care Fund 2016-03-31 Add0.13%$29.05 - $79.38
($40.36)
$ 49.5823%Add 25.56%8,603,676
ALKSGeorge Soros 2016-03-31 Sold Out -0.01%$29.05 - $79.38
($40.36)
$ 49.5823%Sold Out0
ALKSKen Fisher 2016-03-31 Reduce$29.05 - $79.38
($40.36)
$ 49.5823%Reduce -0.02%120,297
ALKSGeorge Soros 2015-12-31 Reduce-0.01%$57.89 - $80.14
($70.39)
$ 49.58-30%Reduce -56.96%3,400
ALKSVanguard Health Care Fund 2015-12-31 Reduce$57.89 - $80.14
($70.39)
$ 49.58-30%Reduce -0.40%6,851,996
ALKSKen Fisher 2015-12-31 Add$57.89 - $80.14
($70.19)
$ 49.58-29%Add 0.34%120,327
ALKSVanguard Health Care Fund 2015-09-30 Add0.08%$55.08 - $72.79
($66.01)
$ 49.58-25%Add 10.43%6,879,583
ALKSGeorge Soros 2015-09-30 Buy 0.01%$55.08 - $72.79
($66.01)
$ 49.58-25%New holding7,900
ALKSKen Fisher 2015-09-30 Add$55.08 - $72.79
($66.01)
$ 49.58-25%Add 11.90%119,920
ALKSVanguard Health Care Fund 2015-03-31 Add$58.24 - $73.64
($68.32)
$ 49.58-27%Add 0.05%6,229,583
ALKSKen Fisher 2014-12-31 Add$40.23 - $58.88
($51.09)
$ 49.58-3%Add 10.18%107,164
ALKSVanguard Health Care Fund 2014-12-31 Add$40.23 - $58.88
($51.09)
$ 49.58-3%Add 0.05%6,226,383
ALKSVanguard Health Care Fund 2014-09-30 Add0.01%$41.54 - $51.75
($44.82)
$ 49.5811%Add 1.42%6,223,083
ALKSKen Fisher 2014-09-30 Add$41.54 - $51.52
($44.73)
$ 49.5811%Add 75.86%97,264
ALKSVanguard Health Care Fund 2014-06-30 Add0.13%$41.1 - $50.94
($46.06)
$ 49.588%Add 18.45%6,135,913
ALKSKen Fisher 2014-06-30 Buy 0.01%$41.1 - $50.94
($46.06)
$ 49.588%New holding55,309
ALKSVanguard Health Care Fund 2014-03-31 Add0.19%$40.07 - $53.82
($47.32)
$ 49.585%Add 41.07%5,180,238
ALKSVanguard Health Care Fund 2013-12-31 Add0.1%$30.17 - $41.12
($36.93)
$ 49.5834%Add 28.18%3,672,087
ALKSVanguard Health Care Fund 2013-09-30 Add0.07%$28.66 - $35.35
($32.58)
$ 49.5852%Add 26.21%2,864,896
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALKS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ALKS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc. 2016-09-22Sell5,000$50.83-2.46view
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc. 2016-09-16Sell5,000$48.871.45view
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc. 2016-09-06Sell10,000$46.027.74view
Brown Iain MichaelSVP Finance & CAO, Alks Inc. 2016-09-06Sell29,976$45.927.97view
Gaffin David JosephSVP, CLO, Alkermes, Inc. 2016-09-06Sell2,382$45.927.97view
MITCHELL PAUL JDirector 2016-09-06Sell2,000$45.927.97view
MITCHELL PAUL JDirector 2016-08-04Sell2,000$49.480.2view
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc. 2016-07-27Sell35,199$51.95-4.56view
MITCHELL PAUL JDirector 2016-07-05Sell2,000$45.818.23view
MITCHELL PAUL JDirector 2016-06-06Sell2,000$44.9810.23view

Quarterly/Annual Reports about ALKS:

News about ALKS:

Articles On GuruFocus.com
AvalonBay Communities, Equinix, Jarden, Alkermes Approach 52-Week Highs Jan 04 2016 
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 08 2011 
Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 05 2010 
Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 
Alkermes Inc. Reports Operating Results (10-K) May 21 2010 
Alkermes Inc. Reports Operating Results (10-Q) Feb 04 2010 
Opportunistic Coat-tailing Jan 05 2010 
Weekly Guru Bargains Highlights: Coinstar Inc, Fair Isaac Corp, Alkermes Inc, American International Dec 12 2009 

More From Other Websites
Virgin Extends Drop As Alaska Air Merger Review Grows Longer Sep 23 2016
ALKERMES PLC. Files SEC form 8-K/A, Change in Directors or Principal Officers Sep 20 2016
Alkermes Announces Webcast of Analyst and Investor Event on September 26, 2016 Sep 19 2016
Alkermes Announces Webcast of Analyst and Investor Event on September 26, 2016 Sep 19 2016
Alkermes Announces Webcast of Analyst and Investor Event on September 26, 2016 Sep 19 2016
Moving Average Crossover Alert: Alkermes (ALKS) Sep 15 2016
Alkermes Launches Competitive Grants Program to Support People Affected by Mental Health and... Sep 12 2016
Alkermes Launches Competitive Grants Program to Support People Affected by Mental Health and... Sep 12 2016
Alkermes Plc – Value Analysis (NASDAQ:ALKS) : September 9, 2016 Sep 09 2016
Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : September 8, 2016 Sep 08 2016
Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference Sep 06 2016
Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference Sep 06 2016
Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference Sep 06 2016
ETF’s with exposure to Alkermes Plc : August 25, 2016 Aug 25 2016
Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : August 24, 2016 Aug 24 2016
Want a Dash for Trash? Why Not Look at Alkermes Aug 15 2016
Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : August 11, 2016 Aug 11 2016
Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA®... Aug 08 2016
Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA®... Aug 08 2016
Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA®... Aug 08 2016
ETF’s with exposure to Alkermes Plc : August 4, 2016 Aug 04 2016
ALKERMES PLC. Financials Aug 03 2016
Alkermes Plc :ALKS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 3, 2016 Aug 03 2016
ALKERMES PLC. Files SEC form 8-K, Other Events Jul 29 2016
Alkermes (ALKS) Posts Narrower Q2 Loss, Ups 2016 Outlook Jul 29 2016
Alkermes Plc Earnings Call scheduled for 8:30 am ET today Jul 28 2016
Alkermes reports 2Q loss Jul 28 2016
Alkermes reports 2Q loss Jul 28 2016
Alkermes plc Reports Second Quarter 2016 Financial Results Jul 28 2016
Q2 2016 Alkermes Plc Earnings Release - Before Market Open Jul 28 2016
ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 28 2016
Alkermes plc Reports Second Quarter 2016 Financial Results Jul 28 2016
Alkermes’ Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare... Jun 01 2016
Alkermes’ Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare... Jun 01 2016
Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors May 26 2016
Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors May 26 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 May 25 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 May 25 2016
Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology... May 24 2016
Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology... May 24 2016
Alkermes reports 1Q loss Apr 28 2016
Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1... Apr 28 2016
Alkermes plc Reports First Quarter 2016 Financial Results Apr 28 2016
Alkermes plc Reports First Quarter 2016 Financial Results Apr 28 2016
Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1... Apr 28 2016
Alkermes to Host Conference Call to Discuss First Quarter 2016 Financial Results Apr 21 2016
Alkermes to Host Conference Call to Discuss First Quarter 2016 Financial Results Apr 21 2016
Alkermes to Present Data on Schizophrenia Portfolio at Upcoming Schizophrenia International Research... Mar 28 2016
Alkermes to Present Data on Schizophrenia Portfolio at Upcoming Schizophrenia International Research... Mar 28 2016
Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference Mar 09 2016
Alkermes reports 4Q loss Feb 25 2016
Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2015 and Provides Financial... Feb 25 2016
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2015 Financial Results Feb 18 2016
Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences Feb 02 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 Jan 25 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 Jan 25 2016
Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in... Jan 21 2016
Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in... Jan 21 2016
Alkermes’ Corporate Presentation to be Webcast at the 34th Annual J.P. Morgan Healthcare... Jan 05 2016
Alkermes’ Corporate Presentation to be Webcast at the 34th Annual J.P. Morgan Healthcare... Jan 05 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)